SynthesisCerebellum (London, England)2025
Machado-Joseph disease in Brazil and other South American countries: A systematic Review and Meta-analysis of Prevalence, CAG Repeat Lengths, Age At Onset, and Ancestry.
Synthesis in Cerebellum (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) is a CAG expansion (CAGexp) disease whose genetic characteristics in South America (SA) are not well known. Our aim was to perform a systematic review and meta-analysis on the subject. Number of SA cases, ages at onset (AO), normal CAG repeats (CAGnormal) and CAGexp, and haplotypes, were searched in Pubmed, Embase, Lilacs, SciELO, ProQuest™ Dissertations & Theses Citation Index, BDTD and La Referencia by a PROSPERO registered protocol. Quantitative data were meta analysed. 26 non-replicated papers and dissertations out of 713 publications were included. 2,111 SCA3/MJD patients were reported, 16 living in Argentina, 10 in Chile, 41 in Venezuela, 18 in Peru, and 2,026 in Brazil between 2011 and 2024. Four individual-participant data (IPD) were obtained. The mean (95% CI; sample size) of CAGnormal, CAGexp and AO were 21.90 (21.53-22.27; 802) and 74.65 (74.43-74.87; 1,100) repeats, and 34.90 (34.25-35.31; 1,102) years. CAGexp explained 62% of the AO variability in IPD (789). The CAGexp effects over AO varied according to geographical origin, impacting in the models to predict AO. It was similar in three Brazilian cohorts, while among Peruvians the AO seemed to be earlier than expected by their CAGexp legths. Three studies found the rs1048755-rs12895357-rs7158733 haplotypes ACA, CCG and AGA in Brazilian patients. In conclusion, current evidence supports the relationship between SCA3/MJD and Portuguese-Azoreans, while the different CAGexp effects on AO across SA populations need to be studied to determine the underlying modifying factors.
Indexed as
Identifiers
40461735What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.